Summer 2025 Bibliography

Association for Accessible Medicines. Generic Medicines. https://accessiblemeds.org/about/generic-medicines/

Azzolino, V et al. Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells. The Journal of Investigative Dermatology. Vol.141,1 (2021): 182-184.e1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7686074/

Barhum L. JAK Inhibitors: Uses, Types, Side Effects, and More. Verywell Health. Updated 2024 Nov 25. https://www.verywellhealth.com/jak-inhibitors-4706526

Boniface K, Seneschal J. Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Experimental Dermatology. Vol. 28,6 (2019): 656-661. https://onlinelibrary.wiley.com/doi/10.1111/exd.13879

Bosworth T. Recent progress in vitiligo treatment might be heading to vitiligo cure. Dermatology News. 2019 August 23. https://www.mdedge.com/dermatology/article/206934/pigmentation-disorders/recent-progress-vitiligo-treatment-might-be?sso=true

Cleveland Clinic. T Cells. https://my.clevelandclinic.org/health/body/24630-t-cells

Fatima, S et al. Systemic therapies in vitiligo: a review. International Journal of Dermatology. Vol. 62,3 (2023): 279-289. https://pubmed.ncbi.nlm.nih.gov/35133006/

Giri, S, Batra L. Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications. Vaccines. Vol.13,2 205. 19 Feb 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11860616/

Harris JE. Speaking of Vitiligo…, Our new research study in Science Translational Medicine describes a new treatment that may have long-term benefit in vitiligo patients. UMass Chan Medical School; Vitiligo Clinical and Research Center. 2018 August 6. https://www.umassmed.edu/vitiligo/blog/blog-posts1/2018/08/science-translational-medicine-journal/

Harris JE. Speaking of Vitiligo…, Update on IL-15 vitiligo treatment. UMass Chan Medical School; Vitiligo Clinical and Research Center. 2020 Jan 13. https://www.umassmed.edu/vitiligo/blog/blog-posts1/2020/01/update-on-il-15-vitiligo-treatment/

Harrison K. Understanding T Cells: T Cell Types, the T Cell Receptor and T Cell Activation, Differentiation and Functions.Technology Networks: Immunology & Microbiology. 2025 Jan 10. https://www.technologynetworks.com/immunology/articles/understanding-t-cells-t-cell-types-the-t-cell-receptor-and-t-cell-activation-differentiation-and-394795#D8

Hu, Z et al. Low-Dose Baricitinib Plus Narrow-Band Ultraviolet B for the Treatment of Progressive Non-Segmental Vitiligo: A Prospective, Controlled, Open-Label Study. Pigment Cell & Melanoma Research. Vol. 38,1 (2025): e13209. https://pmc.ncbi.nlm.nih.gov/articles/PMC11681843/

Jameson S, Masopust D. Understanding Subset Diversity in T Cell Memory. Immunity. Vol. 48,2 (2018): 214-226. https://pmc.ncbi.nlm.nih.gov/articles/PMC5863745/

Kim, SR et al. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. JAMA Dermatology. Vol. 154,3 (2018): 370-371. https://pubmed.ncbi.nlm.nih.gov/29387870/

Li, X et al. Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy. Clinical, Cosmetic and Investigational Dermatology. Vol. 16 635-638.11 Mar. 2023, S396430. https://pmc.ncbi.nlm.nih.gov/articles/PMC10015970/

Liu, L et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal of the American Academy of Dermatology. 2017 Oct. Vol. 77(4)675-682.e1. https://pubmed.ncbi.nlm.nih.gov/28823882/

Mohammed A, Lengyel A, et al. Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis. Dermatology and Therapy Vol.15,7 (2025): 1657-1679. https://pmc.ncbi.nlm.nih.gov/articles/PMC12126450/

Oakes K. Topical ruxolitinib looks good for facial vitiligo, in phase 2 study. Dermatology. 2019 June 26. https://www.mdedge.com/dermatology/article/203617/pigmentation-disorders/topical-ruxolitinib-looks-good-facial-vitiligo

Palmer W. Breakthrough vitiligo treatment offers longer-lasting results. Dermatology Times. 2019 March 2
https://www.dermatologytimes.com/view/breakthrough-vitiligo-treatment-offers-longer-lasting-results

Pizzolla A, Wakim L. Memory T Cell Dynamics in the Lung during Influenza Virus Infection. Journal of Immunology. Baltimore, MD: 1950. Vol. 202,2: 374-381. 2019 Jan 15. https://pubmed.ncbi.nlm.nih.gov/30617119/

Qi, F et al. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Frontiers in Immunology. Vol. 12 790125. 18 Nov. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8636851/, https://pubmed.ncbi.nlm.nih.gov/34868078/

Richmond, J et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Science Translational Medicine. Vol. 10,450 (2018): eaam7710. https://pmc.ncbi.nlm.nih.gov/articles/PMC6495055/

Richmond, J et al. Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. The Journal of Investigative Dermatology. Vol 139,4 (2019): 769-778. https://pmc.ncbi.nlm.nih.gov/articles/PMC6431571/

Riding R, Harris JE. The Role of Memory CD8+ T Cells in Vitiligo. Journal of Immunology. (Baltimore, Md. : 2019 July 1;203(1): 11-19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6709670/

Rosato P et al. Tissue resident memory T cells and viral immunity. Current Opinion in Virology. Vol. 22 (2017): 44-50. https://pmc.ncbi.nlm.nih.gov/articles/PMC5346042/

Sáenz LM, Villarreal JDM. Unlocking the Potential of Baricitinib for Vitiligo. Cutis. Vol.114,3 (2024): 95-96. https://pubmed.ncbi.nlm.nih.gov/39413324/

Samuel, C et al. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatology and Therapy. Vol. 13,3 (2023): 729-749. https://pmc.ncbi.nlm.nih.gov/articles/PMC9930707/

Seneschal, J et al. Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial. JAMA Dermatology. 10.1001/jamadermatol.2024.5737. 22 Jan. 2025. https://pubmed.ncbi.nlm.nih.gov/39841460/

Seong SH, Oh SH. Up-and-Coming Drugs for the Treatment of Vitiligo. Ann Dermatol. 2024 Aug;36(4):197-208. https://anndermatol.org/DOIx.php?id=10.5021/ad.24.038

Utama, A et al. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review International Journal of Dermatology. Vol. 63,8 (2024): 1020-1035. https://onlinelibrary.wiley.com/doi/10.1111/ijd.17157

Watanabe, R. Protective and pathogenic roles of resident memory T cells in human skin disorders. Journal of Dermatological Science. Vol. 95,1 (2019): 2-7. https://pubmed.ncbi.nlm.nih.gov/31272851/

Additional text: https://www.sciencedirect.com/science/article/abs/pii/S0923181119301471

Wikipedia. Tissue Resident Memory T cell Tissue-resident memory T cell – Wikipedia